home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

223 rows where filing_period = "third_quarter", filing_year = 2015 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 223 ✖

filing_year 1

  • 2015 · 223 ✖

filing_period 1

  • third_quarter · 223 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1725366 HOSPIRA, INC. d19b7cb7-90d5-4ea3-83e7-9751414b741d 3T HOSPIRA, INC. 318711 HOSPIRA INC 2015 third_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) HOUSE OF REPRESENTATIVES,SENATE   270000 0 1 2015-08-31T13:17:30.527000-04:00
1725602 RED+BLUE STRATEGIES d25f517f-5613-4316-90c3-92651ad3ead8 3T RED+BLUE STRATEGIES 400693064 HOSPIRA 2015 third_quarter PHA Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace. HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2015-09-09T15:21:43.843000-04:00
1726164 PRINTING INDUSTRIES OF AMERICA, INC. 7feada52-8d13-4f29-a047-b899b67f58b2 3A PRINTING INDUSTRIES OF AMERICA, INC. 32203 PRINTING INDUSTRIES OF AMERICA INC 2015 third_quarter PHA Pharmaceutical Printed Literature Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS)   105705 0 0 2015-10-01T13:00:14.633000-04:00
1726680 HOLLAND & KNIGHT LLP d12bf0d4-19de-456a-887f-7f607b0013f2 Q3 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2015 third_quarter PHA Advocating for policy to ensure patient access to pain relief. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-05T14:24:00.850000-04:00
1727180 AMERICAN COLLEGE OF CLINICAL PHARMACY 040accba-841d-4b31-9137-c049aa19fcfa Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2015 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   127250 0 0 2015-10-07T14:56:58.347000-04:00
1727634 UNIVERSITY OF IOWA 1305704d-37e1-4d49-a12d-f4b228df1e6e 3A UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2015 third_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   86662 0 0 2015-10-09T10:35:55.577000-04:00
1728000 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 082fe641-7a93-47c9-9610-7b27db8b3b04 Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2015 third_quarter PHA H.R. 793 - Ensuring Seniors Access to Local Pharmacies Act of 2015; H.R. 244 - MAC Transparency Act of 2015; Congressional Oversight of 340 B Program; S. 1200 - Fairness to Pet Act Legislation 2015; S. 1190 -Ensuring Seniors Access to Local Pharmacies Act of 2015; S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 592 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3174 - Fairness to Pet Owners Act of 2015; S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE   575000 0 0 2015-10-09T16:14:30.907000-04:00
1728119 MR. VINCENT A. PANVINI 498f8805-54f9-4aef-ae96-c212394b1a4b Q3 MR. VINCENT A. PANVINI 401008845 PHRMA 2015 third_quarter PHA Trans-Pacific Partnership Patent Reform HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-10-10T16:43:02.910000-04:00
1728593 ASSOCIATION OF NATIONAL ADVERTISERS, INC. cf1bb936-0d1f-4080-aa69-584a3066c863 Q3 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2015 third_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   430000 0 0 2015-10-12T16:15:06.290000-04:00
1728968 ROCK & ASSOCIATES 8071eeff-b121-454d-a7cf-b3ebc57ea414 Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T10:53:59.250000-04:00
1728972 ROCK & ASSOCIATES 8e82ac35-026e-4aa0-84f9-27a2066b0d22 Q3 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T10:55:04.093000-04:00
1728978 ROCK & ASSOCIATES 3a5e5170-88a5-4b56-be4b-62b109c7f866 Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T10:57:09.577000-04:00
1728984 ROCK & ASSOCIATES 0439e212-32f0-498a-8662-08ce5e53f355 Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T10:59:13.827000-04:00
1728995 ROCK & ASSOCIATES f303e540-49ca-418d-bca0-8b759948b02f Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T10:59:19.017000-04:00
1729004 ROCK & ASSOCIATES 43e940e7-397b-4930-88d8-58bd2af38e16 Q3 ROCK & ASSOCIATES 33545 US COMPOUNDING 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T11:01:23.657000-04:00
1729010 ROCK & ASSOCIATES 578f1bfc-2d22-4dd2-b7ba-081bbca0a3d9 3A ROCK & ASSOCIATES 33545 US COMPOUNDING 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-10-13T11:03:30.127000-04:00
1729017 ROCK & ASSOCIATES da0391ae-6cf7-4694-9728-f2ddf7af3d0c Q3 ROCK & ASSOCIATES 33545 TOWN & COUNTRY COMPOUNDING AND CONSULTING 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-10-13T11:05:34.847000-04:00
1729020 ROCK & ASSOCIATES c94c3dd5-98aa-401f-851e-082f00a9eac0 Q3 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-10-13T11:06:39.830000-04:00
1729149 THE STRATEGY GROUP, INC. 7c319583-128f-4f06-adcc-b93a2458f3db Q3 THE STRATEGY GROUP, INC. 401103637 PHRMA 2015 third_quarter PHA 340B Pharmacy Program. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-13T12:16:43.447000-04:00
1729387 PARRY, ROMANI, DECONCINI & SYMMS 271db916-c87d-4a1a-aaa5-75dc1b1d1801 Q3 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2015-10-13T14:28:39.243000-04:00
1729690 PARRY, ROMANI, DECONCINI & SYMMS 2b3f2776-1f93-4ee9-b4be-3e99393ef239 3A PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2015 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 21000   0 0 2015-10-13T16:38:35.633000-04:00
1730345 ACG ADVOCACY b211f9af-a9a2-4d5f-bf89-6fd0e803495e Q3 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2015 third_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-14T12:58:27.127000-04:00
1730626 SANOFI US SERVICES INC. cf8c4aa2-b918-4273-b8b2-6a702e5ee770 Q3 SANOFI US SERVICES INC. 56838 SANOFI US SERVICES INC 2015 third_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE   1170000 0 0 2015-10-14T14:15:42.777000-04:00
1730628 TCH GROUP, LLC bc30f584-d8d9-4eb0-99fe-62ae9026281d Q3 TCH GROUP, LLC 51478 CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2015 third_quarter PHA S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015 SENATE 20000   0 0 2015-10-14T14:17:49.293000-04:00
1731125 KENT & O'CONNOR, INC. 2a404642-d0fb-42b7-ae6d-4d35d05258b4 Q3 KENT & O'CONNOR, INC. 21426 INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION 2015 third_quarter PHA Legislation and regulations relating to drug and safety issues. Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection 30000   0 0 2015-10-15T09:33:41.560000-04:00
1731184 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 84cd3189-42be-4296-b638-e123a18079c5 Q3 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2015 third_quarter PHA Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   100000 0 0 2015-10-15T09:51:30.560000-04:00
1731724 THE D MAJOR GROUP 5d14e130-01ba-4f5d-ae33-7abeccddc49c Q3 THE D MAJOR GROUP 401103162 CVS CAREMARK 2015 third_quarter PHA Issues related to innovation in pharmacy delivery, including health information technology. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-15T12:21:29.187000-04:00
1732122 CHRISTY ELLERBEE CONSULTING, LLC 6a772079-e1e0-4638-98e6-2816aecd8015 Q3 CHRISTY ELLERBEE CONSULTING, LLC 401103332 INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) 2015 third_quarter PHA H.R. 2872 Opioid Addiction Treatment Modernization Act. H.R. 1821 and S. 707 Opioid Overdose Reduction Act of 2015. H.R. 2536 and S. 1455 TREAT ACT. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-10-15T14:34:29.793000-04:00
1732231 INDEPENDENT PHARMACY COOPERATIVE 43c7ed64-3998-4d19-ad1d-cef9a64b89b1 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2015 third_quarter PHA H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. HR 6 21st Century Cures Act. IPC is not supportive of some of the "pay for" provisions. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-10-15T15:03:12.763000-04:00
1732454 VALENTE & ASSOCIATES c69edfbb-2fb3-4166-8a76-68a8ebae0c7a Q3 VALENTE & ASSOCIATES 45983 SAV-MOR FRANCHISING, INC. 2015 third_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES 30000   0 0 2015-10-15T16:16:27.383000-04:00
1732476 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 96987ac3-46ec-43fd-89df-cd48add4a3c5 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2015 third_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections S. 1532 - Affordability is Access Act. Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   260000 0 0 2015-10-15T16:20:42.367000-04:00
1732911 NELSON MULLINS RILEY & SCARBOROUGH fd53c62c-fd5e-4f6c-9c76-32fc675f72f3 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2015 third_quarter PHA Issues related to 340B Drug Pricing Progam HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-16T08:34:54.420000-04:00
1732916 NELSON MULLINS RILEY & SCARBOROUGH 1090f700-f9d1-42a5-a023-0402dd41fa41 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2015 third_quarter PHA Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-16T08:37:58.327000-04:00
1732950 WILLIAMS AND JENSEN, PLLC 7941b268-e180-4386-8d52-8ea2471feefe Q3 WILLIAMS AND JENSEN, PLLC 41454 FAGRON NORTH AMERICA 2015 third_quarter PHA Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-16T08:47:26.017000-04:00
1733020 AMERICAN VETERINARY MEDICAL ASSOCIATION 1bc29771-b831-417f-a5de-a6b763413d93 3A AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2015 third_quarter PHA Guidance for Industry: Compounding Animal Drugs from Bulk Substances Discussions with Congressional staff, FDA and USDA regarding the use of antimicrobials in food-producing animals, particularly with respect to H.R.1552 (Preservation of Antibiotics for Medical Treatment Act), S. 621 (Preventing Antibiotic Resistance Act), and FDA's strategy (GRI #209 and VFD Rule) Discussions with Congressional staff, FDA and Government Accountability Office to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Inquiries to, and discussions with, Congressional staff on veterinary pet prescriptions, particularly regarding H.R. 317/S. 1200, the Fairness to Pet Owners Act. Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2015-10-16T09:05:14.283000-04:00
1733025 NELSON MULLINS RILEY & SCARBOROUGH ef8ec07d-9ce6-47d9-9332-e21ba6d76f4b Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2015 third_quarter PHA Any legislation and regulation to the treatment of opioid abuse. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-10-16T09:08:18.190000-04:00
1733039 ALKERMES, INC. ce123943-bfb5-48ae-8ac4-c58ab1d13560 Q3 ALKERMES, INC. 400458235 ALKERMES, INC. 2015 third_quarter PHA Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   702000 0 0 2015-10-16T09:17:33.987000-04:00
1733139 RED+BLUE STRATEGIES 14084089-df2a-4b8f-9f26-ad483319bf3a Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2015 third_quarter PHA H.R.6 - 21st Century Cures - Issues related to exclusivity rights of certain prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-16T10:01:25.977000-04:00
1733201 RED+BLUE STRATEGIES c168b005-fb7f-423a-a485-eb74947e8340 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2015 third_quarter PHA H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. Issues related to patents and the treatment of prescription medications. Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-16T10:19:23.057000-04:00
1733210 RED+BLUE STRATEGIES 4f0e6c96-a63a-40ee-b5d7-72185e78fce7 Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2015 third_quarter PHA H.R. 6 - 21st Century Cures Act - Issues related to ensuring that medically needed antibiotics are available to the public, curbing opioid abuse in Medicare Part D and maintaining the integrity of the federal Open Payments program. S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation. Support of the inclusion of Advanced Care Planning codes in the CMS Physician Fee Schedule (PFS). S. 633 - The Promise for antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Advancing provisions to highlight Antibiotic Innovation in the President's FY 2016 budget. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-16T10:23:32.760000-04:00
1733367 RED+BLUE STRATEGIES 73f6c2fe-09f2-4b09-b090-fdc424f6a51b Q3 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2015 third_quarter PHA H.R. 6 - 21st Century Cures - Issues related to supporting programs to prevent opioid abuse in the Part D program. Issues related to opioid abuse. Issues related to state-based marketplaces. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-16T10:52:54.170000-04:00
1733387 COREWELL HEALTH 3f46ec53-7c59-4854-b2a5-4549748b8190 Q3 COREWELL HEALTH 298455 COREWELL HEALTH 2015 third_quarter PHA Discussions regarding value of 340B Pharmacy Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2015-10-16T10:55:07.030000-04:00
1733423 MERCURY PUBLIC AFFAIRS, LLC b9c1c7d4-64b6-4df1-907b-4b3327db98d5 Q3 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2015 third_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2015-10-16T11:05:52.580000-04:00
1733503 JOHNS HOPKINS UNIVERSITY d9ea2d39-5442-4ae0-bd30-7ecb6f38c32e Q3 JOHNS HOPKINS UNIVERSITY 20664 JOHNS HOPKINS UNIVERSITY 2015 third_quarter PHA Pharmaceutical drug price increases; 340B drug discount program HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2015-10-16T11:16:59.657000-04:00
1733590 RED+BLUE STRATEGIES 50d58cc8-6b91-4402-9033-a5f6606e9d89 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2015 third_quarter PHA CMS Proposed Physician Fee Schedule(PFS) with a focus on provisions dealthing with the treatment of Medicare's reimbursement for a new class of prescription medications, Biosimilars. Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 20000   0 0 2015-10-16T11:32:18.847000-04:00
1733758 BLUESTONE STRATEGIES, LLC 1677813a-495f-4f35-bfea-429a0049595f Q3 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2015 third_quarter PHA Specialty Drugs and Drug Pricing HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-16T11:59:41.037000-04:00
1733809 BLUESTONE STRATEGIES, LLC 91292c12-8e63-4675-91b6-9c8b7d72b7cb Q3 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2015 third_quarter PHA Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; HR 6, the 21st Century Cures Act; S. 1413, RX Abuse and Prevention; S.1913, Pharmacy Lock-In HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-16T12:11:38.667000-04:00
1733827 NOVO NORDISK INC. cc56ab2d-3c34-4444-a37b-f4379c4b421c Q3 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2015 third_quarter PHA P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   620000 0 0 2015-10-16T12:15:55.493000-04:00
1733984 CHAMBER HILL STRATEGIES b6734469-1758-46a7-a469-fede3c08630a Q3 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2015 third_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-16T12:57:57.997000-04:00
1734099 ACADEMY OF MANAGED CARE PHARMACY 024ede9b-c346-49ac-84d5-d208110ab349 Q3 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2015 third_quarter PHA Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   210000 0 0 2015-10-16T13:30:08.783000-04:00
1734224 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION cdc649ec-d291-4d3a-98b6-14a6629be6cb 3A PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2015 third_quarter PHA Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   622142 0 0 2015-10-16T13:58:28.803000-04:00
1734937 THE STRATEGY GROUP, INC. 22667963-b981-43ae-a62a-ea4537e8e2c5 3A THE STRATEGY GROUP, INC. 401103637 PHRMA 2015 third_quarter PHA 340B Pharmacy Program. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-16T16:11:35.367000-04:00
1735155 THORSEN FRENCH ADVOCACY LLC 46eca8e3-35ad-41a0-880d-e0cdb646e9e6 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2015 third_quarter PHA Issues related to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-10-16T16:52:17.680000-04:00
1735169 SAFEWAY INC. affaadbe-5f52-4b03-9292-474f5f212786 Q3 SAFEWAY INC. 300173 SAFEWAY 2015 third_quarter PHA H.R. 592/S. 314 -- Pharmacy and Underserved Areas Enhancement Act, all provisions. Draft Proposal: Preserve Access to Community Pharmacies in TRICARE. HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2015-10-16T16:54:30.403000-04:00
1735372 THE INGRAM GROUP LLC b097d107-4b34-4f8a-aaba-2151ff98c723 Q3 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2015 third_quarter PHA S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.6, 21st Century Cures Act. General issues related to the biopharmaceutical and pharmaceutical industries. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-10-16T17:45:49.073000-04:00
1735379 THORSEN FRENCH ADVOCACY LLC fd6ba951-2497-4b11-86ef-5bde16298734 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2015 third_quarter PHA Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-16T17:46:59.823000-04:00
1736704 FLYNN & ASSOCIATES, INC. ba7b39f4-28ed-4f59-85ba-9ae8aa1d7585 Q3 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2015 third_quarter PHA Medicare Part-D rebates Trade agreements Patent reform legislation H.R. 9 HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-18T15:04:40.223000-04:00
1736877 EMPIRE CONSULTING GROUP 8647783b-df86-440e-bab8-c7c2466a2583 Q3 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2015 third_quarter PHA Medicare Prescription Drug Act; HR 9, Innovation Act; 21st Century Cures Act; prescription drug costs; Trans Pacific Partnership (TPP) Agreement (provisions relating to data protection for biologics);and budget reconciliation legislation (provisions relating to healthcare). HOUSE OF REPRESENTATIVES 40000   0 0 2015-10-18T21:31:16.157000-04:00
1737129 NATIONAL RURAL HEALTH ASSOCATION 97c0afc4-8120-4b75-815e-113dbbdbfdc1 Q3 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2015 third_quarter PHA Support for 340B program HOUSE OF REPRESENTATIVES,SENATE   25924 0 0 2015-10-19T09:27:04.567000-04:00
1737181 ELI LILLY AND COMPANY ce05564f-2f31-45c1-8577-1e2f6a7bfa96 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2015 third_quarter PHA Hospital discounts; 340B Program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1630000 0 0 2015-10-19T09:42:52.927000-04:00
1737199 APOTEX CORP. 82670507-fcea-4733-83cc-bc98e74a9569 Q3 APOTEX CORP. 310973 APOTEX CORP. 2015 third_quarter PHA HR 6, The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to issues affecting the generic drug industry within the Senate Health, Education, Labor and Pensions Committee's Innovation for Healthier Americans initiative; HR 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 1137, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periods; S. 2109, The Preserve Access to Affordable Generics Act, provisions relating to the legality of patent settlements between brand and generic pharmaceutical companies; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and FDA proposed rule, Designation of Official Names for Certain Biological Products, Docket No. FDA-2015-N-0648, provisions related to nonproprietary naming for biologic products HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2015-10-19T09:46:02.460000-04:00
1737297 PRIME POLICY GROUP 83d2cbf4-6a41-4584-b21d-d5d769771378 Q3 PRIME POLICY GROUP 400532589 GLAXOSMITHKLINE 2015 third_quarter PHA Vaccines Drug Pricing HOUSE OF REPRESENTATIVES,SENATE,White House Office 40000   0 0 2015-10-19T10:14:52.837000-04:00
1737555 GILEAD SCIENCES, INC. 12e22244-1ab3-44e0-8945-ff0a0b800bcb Q3 GILEAD SCIENCES, INC. 287177 GILEAD SCIENCES INC 2015 third_quarter PHA Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B. Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA)   700000 0 0 2015-10-19T11:02:49.813000-04:00
1737921 TEVA PHARMACEUTICALS USA, INC. 7e993854-227b-47d1-9b8b-f9aa102aba33 Q3 TEVA PHARMACEUTICALS USA, INC. 76695 TEVA PHARMACEUTICALS USA INC 2015 third_quarter PHA Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   990000 0 0 2015-10-19T11:41:47.833000-04:00
1738109 AMERICAN PHARMACISTS ASSOCIATION 678e999e-79d7-45d1-9249-81fa0066b709 Q3 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2015 third_quarter PHA Reimbursement of pharmacist services - HR592/S314 Transitions of care Risk evaluation and mitigation services Track and trace/supply chain Health information technology Immunizations Compounding Tele-medicine Quality rating AMP FULs Biosimiliars Drug importation Generics labeling Preferred pharmacy network - HR793 Electronic labeling Home infusion - HR605/S275 21st century cures Drug Disposal Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   27243 0 0 2015-10-19T12:00:04.743000-04:00
1738267 WALTER CONSULTING 9373b789-58e9-4e51-af0d-7973386e7b3d Q3 WALTER CONSULTING 301697 AMERISOURCEBERGEN CORPORATION 2015 third_quarter PHA H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-10-19T12:18:48.027000-04:00
1738345 BLUECROSS BLUESHIELD OF TENNESSEE 97b8847e-e8ab-407e-ad4d-be90dbe684fa Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2015 third_quarter PHA General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse; specialty drug pricing Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2015-10-19T12:29:24.557000-04:00
1738446 BROWN RUDNICK LLP eeca671d-79d1-4922-922c-de976a83089d Q3 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2015 third_quarter PHA Issues relating to Implementation of P.L. 113 - 54 (Drug Quality and Security Act); H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 480, H.R. 1725-relating to Prescription Drug Monitoring Programs; S. 524 & H.R. 953 relating to prescription drug abuse HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-10-19T12:46:02.123000-04:00
1738753 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY dfeae908-27b0-40c4-9414-93f9630a89dc Q3 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY 72793 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY 2015 third_quarter PHA Pharmaceutical Innovation; Patent Reform; Senate HELP Cures Bill information HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2015-10-19T13:20:14.047000-04:00
1738800 WAXMAN STRATEGIES 0eedd3b2-3d68-4f15-8282-12e124adba62 Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2015 third_quarter PHA Laws and regulations affecting the 340B Drug Discount Program Health & Human Services, Dept of (HHS) 18750   0 0 2015-10-19T13:26:03.080000-04:00
1738806 KAISER FOUNDATION HEALTH PLAN INC. 5c0de7bc-e77a-4e2e-8219-dbe29ab131c3 Q3 KAISER FOUNDATION HEALTH PLAN INC. 21027 KAISER FOUNDATION HEALTH PLAN INC 2015 third_quarter PHA S 1137 - PATENT Act, Protecting American Talent and Entrepreneurship Act of 2015: A bill to amend title 35, United States Code, and the Leahy-Smith America Invents Act to make improvements and technical corrections, and for other purposes. Grassley (R-IA) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2015-10-19T13:27:05.190000-04:00
1738955 SLC HEALTH STRATEGIES, LLC 93613ec1-795a-4338-967c-53334ee617ad Q3 SLC HEALTH STRATEGIES, LLC 401018877 NOVO NORDISK PHARMACEUTICALS, INC. 2015 third_quarter PHA HR 6 - 21st Century Cures Act FDA issues regarding biosimilar products; 340B program matters HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2015-10-19T13:45:27.897000-04:00
1739104 ISEMAN & ASSOCIATES LLC c18877d8-ea88-4d24-be52-88bb0c9c7327 Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2015 third_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-19T13:59:48.100000-04:00
1739236 BROWN RUDNICK LLP 4fd866db-a7ee-4f0e-99cf-cab0e8b014e8 Q3 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2015 third_quarter PHA HR 793 - Ensuring Seniors Access to Local Pharmacies Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-19T14:10:52.757000-04:00
1739262 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 4db32106-d1ca-489e-8c47-b8deefd2dc31 Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2015 third_quarter PHA Pharmaceutical innovation and patent reform H.R. 6 - Introduced May 19, 2015 by Rep. Fred Upton, The 21st Century Cures Act Provisions related to bringing medical treatments to market faster with monies allocated to Medicare Part D Reinsurance HOUSE OF REPRESENTATIVES,SENATE   178269 0 0 2015-10-19T14:13:19.803000-04:00
1739311 BROWN RUDNICK LLP 201231ef-fd99-4117-94b4-670d042f26d3 Q3 BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2015 third_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to abuse deterrent drug development HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-10-19T14:17:07.727000-04:00
1739340 BROWN RUDNICK LLP 1e9c1249-d712-4a53-a4e9-6bbc4bb0319a Q3 BROWN RUDNICK LLP 287895 EXELA HOLDINGS, LLC 2015 third_quarter PHA Issues relating to ANDA review and approval Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-19T14:18:26.507000-04:00
1739364 BROWN RUDNICK LLP f8d37404-96ee-430d-a336-9e05fe530101 Q3 BROWN RUDNICK LLP 287895 ZYDUS PHARMACEUTICALS USA INC. 2015 third_quarter PHA Issues relating to generic drug pricing HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-19T14:20:43.507000-04:00
1739412 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 51189100-5076-445f-8938-2232e6bf3248 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2015 third_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2015-10-19T14:24:26.587000-04:00
1739426 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 411eb8dd-ee10-458a-9f21-a36647cad96d Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2015 third_quarter PHA HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2015-10-19T14:25:37.290000-04:00
1739467 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f0b98046-869f-4cdd-8474-5d744384b069 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2015 third_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 1600, Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2015-10-19T14:26:55.820000-04:00
1739520 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 6098c223-8865-453c-baed-26ff08cd7666 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2015 third_quarter PHA issues related to the 340B drug discount program; HR 6, 21st Century Cures potential amendment Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-19T14:29:21.603000-04:00
1739669 KOUNTOUPES DENHAM CARR & REID, LLC b5765f8e-d9c3-4206-b040-17f35a978801 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2015 third_quarter PHA General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to H.R. 6, "21st Century Cures" as well as FDA and NIH modernization. Draft legislation regarding microbeads in over the counter products; Issues related to the over the counter drug monograph process. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-19T14:40:11.557000-04:00
1739759 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 4e6ebef7-0694-4508-baa9-5ad14f4dc9ff Q3 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 401097063 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 2015 third_quarter PHA 340B Program support to maintain current level of funding and discounts Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   30271 0 0 2015-10-19T14:49:19.120000-04:00
1739852 FTI GOVERNMENT AFFAIRS d065d905-cca3-4e2f-a787-0fc5f4d51ed2 Q3 FTI GOVERNMENT AFFAIRS 401054971 PERRIGO, INC. 2015 third_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2015-10-19T14:57:34.590000-04:00
1739927 ANIMAL HEALTH INSTITUTE 7b090eb9-8706-47c5-88eb-6f2390f28379 Q3 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2015 third_quarter PHA Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions from Environmental Assessments for animal health products; HR 3174 and S 1200 - Fairness to Pet Owners Act HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2015-10-19T15:01:18.483000-04:00
1739961 FOLEY & LARDNER LLP 5167e925-b315-4881-808c-8612b7440e5e Q3 FOLEY & LARDNER LLP 15042 PAR PHARMACEUTICAL 2015 third_quarter PHA FDA issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-19T15:02:42.920000-04:00
1740287 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 09ec1c96-66fd-489a-9653-7e38edada480 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2015 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact with GAO on pharmacy compounding. Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2015-10-19T15:29:39.500000-04:00
1740492 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) a6396ba9-47cb-4949-878d-0d5aa337efb2 Q3 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2015 third_quarter PHA Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   309992 0 0 2015-10-19T15:41:54.360000-04:00
1741004 MR. GALEN RESER a129ab7f-b1f8-4a3e-b6fa-ae7b54c17fc0 Q3 MR. GALEN RESER 401055978 PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) 2015 third_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-10-19T16:12:31.270000-04:00
1741082 ALLERGAN USA, INC. fb6de475-63ea-4241-900a-24aed77d7f88 Q3 ALLERGAN USA, INC. 63837 ALLERGAN USA, INC. 2015 third_quarter PHA Drug Labeling Drug Importation Track and Trace Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE   850000 0 0 2015-10-19T16:17:13-04:00
1741607 WEST FRONT STRATEGIES LLC 5fb5a2c8-97dd-4b08-9304-3a6cbec3ae90 Q3 WEST FRONT STRATEGIES LLC 401103493 WALGREEN CO. 2015 third_quarter PHA Pharmacy and Medically Underserved Areas Enhancement Act (S. 314 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-19T16:52:33.543000-04:00
1741788 CAPITOL HILL CONSULTING GROUP c3cfefb8-88c8-470c-b174-a91ace0256e6 Q3 CAPITOL HILL CONSULTING GROUP 72053 ENDO PHARMACEUTICALS 2015 third_quarter PHA Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825 HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-19T17:05:38.183000-04:00
1742101 THE SIMMONS & RUSSELL GROUP, LLC 51691d0b-9a3b-4c01-bb1f-925d6ca7a9d8 Q3 THE SIMMONS & RUSSELL GROUP, LLC 401103235 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2015 third_quarter PHA Drug importation and the FAIR Generics legislation; An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025, S.CON.RES.11. SENATE 60000   0 0 2015-10-19T17:35:40.173000-04:00
1742109 GREATER NEW YORK HOSPITAL ASSOCIATION 3bef94f8-3a08-4880-b19a-307a1c9ac723 Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2015 third_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08). Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   300000 0 0 2015-10-19T17:36:43.220000-04:00
1742376 EXPRESS SCRIPTS, INC. 174172a0-a514-4853-8273-f9cfb0ccfbdc Q3 EXPRESS SCRIPTS, INC. 294416 EXPRESS SCRIPTS, INC. 2015 third_quarter PHA Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office   520000 0 0 2015-10-19T18:06:50.377000-04:00
1742485 KING & SPALDING LLP 4c6e81cd-c801-4f8e-a94b-a059e3486410 Q3 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2015 third_quarter PHA Issues related to inclusion of prescription drugs within Essential Health Benefit; H.R. 2646, Helping Families in Mental Health Crisis Act of 2015; S. 1945, Mental Health Reform Act of 2015; and mental health coverage expansion HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-10-19T18:29:00.380000-04:00
1742491 OREGON HEALTH & SCIENCE UNIVERSITY 68711fb7-8ec7-45b0-beae-99edbe714b68 Q3 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2015 third_quarter PHA 340b Drug Discount Program for safety net hospitals. HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2015-10-19T18:29:04.693000-04:00
1743004 BLUE CROSS AND BLUE SHIELD ASSOCIATION f17abd42-c621-4b9c-8fa6-31e6aec87b86 Q3 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2015 third_quarter PHA Pharmaceutical Innovation; Patent Reform; HELP Cures Bill Information Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office   2110000 0 0 2015-10-19T22:03:24.853000-04:00
1743388 BRAVO GROUP 5c7d7163-df4c-47e5-941b-7e284fdd9f3a Q3 BRAVO GROUP 296293 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2015 third_quarter PHA Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-10-20T08:14:55.040000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 3271.482ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API